• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptose Biosciences Inc (OP:APTOF)

1.640 UNCHANGED
Streaming Delayed Price Updated: 1:52 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.640
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.640
Today's Range 1.640 - 1.640
52wk Range 0.6363 - 4.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
July 15, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Upgraded to Trade on OTCQB Market
July 01, 2025
Aptose will trade under the ticker symbol APTOF and begin trading on OTCQB today, July 1st 
From Aptose Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-18.4%
-18.4%
1 Month
+81.1%
+81.1%
3 Month
-29.0%
-29.0%
6 Month
-18.4%
-18.4%
1 Year
-18.4%
-18.4%

More News

Read More
Aptose Announces Deferral of Interest Payment
June 30, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
June 20, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Provides Corporate Updates
June 17, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
June 12, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Results from Annual and Special Meeting of Shareholders
May 27, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
May 20, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
May 14, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports First Quarter 2025 Results
May 08, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Aptose Biosciences Inc publicly traded?
Yes, Aptose Biosciences Inc is publicly traded.
What exchange does Aptose Biosciences Inc trade on?
Aptose Biosciences Inc trades on the OTC Traded
What is the ticker symbol for Aptose Biosciences Inc?
The ticker symbol for Aptose Biosciences Inc is APTOF on the OTC Traded
What is the current price of Aptose Biosciences Inc?
The current price of Aptose Biosciences Inc is 1.640
When was Aptose Biosciences Inc last traded?
The last trade of Aptose Biosciences Inc was at 07/23/25 01:52 PM ET
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap